1
|
Zhao W, Zhao B, Meng X, Li B, Wang Y, Yu F, Fu C, Yu X, Li X, Dai C, Wang J, Gao H, Cheng M. The regulation of MFG-E8 on the mitophagy in diabetic sarcopenia via the HSPA1L-Parkin pathway and the effect of D-pinitol. J Cachexia Sarcopenia Muscle 2024; 15:934-948. [PMID: 38553831 PMCID: PMC11154748 DOI: 10.1002/jcsm.13459] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/28/2023] [Revised: 02/26/2024] [Accepted: 03/05/2024] [Indexed: 06/07/2024] Open
Abstract
BACKGROUND Diabetic sarcopenia is a disease-related skeletal muscle disorder that causes progressive symptoms. The complete understanding of its pathogenesis is yet to be unravelled, which makes it difficult to develop effective therapeutic strategies. This study investigates how MFG-E8 affects mitophagy and the protective role of D-pinitol (DP) in diabetic sarcopenia. METHODS In vivo, streptozotocin-induced diabetic SAM-R1 (STZ-R1) and SAM-P8 (STZ-P8) mice (16-week-old) were used, and STZ-P8 mice were administrated of DP (150 mg/kg per day) for 6 weeks. Gastrocnemius muscles were harvested for histological analysis including transmission electron microscopy. Proteins were evaluated via immunohistochemistry (IHC), immunofluorescence (IF), and western blotting (WB) assay. In vitro, advanced glycation end products (AGEs) induced diabetic and D-galactose (DG) induced senescent C2C12 models were established and received DP, MFG-E8 plasmid (Mover)/siRNA (MsiRNA), or 3-MA/Torin-1 intervention. Proteins were evaluated by IF and WB assay. Immunoprecipitation (IP) and co-immunoprecipitation (CO-IP) were used for hunting the interacted proteins of MFG-E8. RESULTS In vivo, sarcopenia, mitophagy deficiency, and up-regulated MFG-E8 were confirmed in the STZ-P8 group. DP exerted protective effects on sarcopenia and mitophagy (DP + STZ-P8 vs. STZ-P8; all P < 0.01), such as increased lean mass (8.47 ± 0.81 g vs. 7.08 ± 1.64 g), grip strength (208.62 ± 39.45 g vs. 160.87 ± 26.95 g), rotarod tests (109.7 ± 11.81 s vs. 59.3 ± 20.97 s), muscle cross-sectional area (CSA) (1912.17 ± 535.61 μm2 vs. 1557.19 ± 588.38 μm2), autophagosomes (0.07 ± 0.02 per μm2 vs. 0.02 ± 0.01 per μm2), and cytolysosome (0.07 ± 0.03 per μm2 vs. 0.03 ± 0.01 per μm2). DP down-regulated MFG-E8 in both serum (DP + STZ-P8: 253.19 ± 34.75 pg/mL vs. STZ-P8: 404.69 ± 78.97 pg/mL; P < 0.001) and gastrocnemius muscle (WB assay. DP + STZ-P8: 0.39 ± 0.04 vs. STZ-P8: 0.55 ± 0.08; P < 0.01). DP also up-regulated PINK1, Parkin and LC3B-II/I ratio, and down-regulated P62 in gastrocnemius muscles (all P < 0.01). In vitro, mitophagy deficiency and MFG-E8 up-regulation were confirmed in diabetic and senescent models (all P < 0.05). DP and MsiRNA down-regulated MFG-E8 and P62, and up-regulated PINK1, Parkin and LC3B-II/I ratio to promote mitophagy as Torin-1 does (all P < 0.05). HSPA1L was confirmed as an interacted protein of MFG-E8 in IP and CO-IP assay. Mover down-regulated the expression of Parkin via the HSPA1L-Parkin pathway, leading to mitophagy inhibition. MsiRNA up-regulated the expression of PINK1 via SGK1, FOXO1, and STAT3 phosphorylation pathways, leading to mitophagy stimulation. CONCLUSIONS MFG-E8 is a crucial target protein of DP and plays a distinct role in mitophagy regulation. DP down-regulates the expression of MFG-E8, reduces mitophagy deficiency, and alleviates the symptoms of diabetic sarcopenia, which could be considered a novel therapeutic strategy for diabetic sarcopenia.
Collapse
Affiliation(s)
- Wenqian Zhao
- Department of Geriatric Medicine, Qilu Hospital, Cheeloo College of MedicineShandong UniversityJinanChina
- Key Laboratory of Cardiovascular Proteomics of Shandong Province, Qilu Hospital, Cheeloo College of MedicineShandong UniversityJinanChina
- Jinan Clinical Research Center for Geriatric Medicine (202132001)JinanChina
| | - Bin Zhao
- Postdoctoral Research StationShandong University of Traditional Chinese MedicineJinanChina
| | - Xinyue Meng
- Department of Geriatric Medicine, Qilu Hospital, Cheeloo College of MedicineShandong UniversityJinanChina
- Key Laboratory of Cardiovascular Proteomics of Shandong Province, Qilu Hospital, Cheeloo College of MedicineShandong UniversityJinanChina
- Jinan Clinical Research Center for Geriatric Medicine (202132001)JinanChina
| | - Baoying Li
- Key Laboratory of Cardiovascular Proteomics of Shandong Province, Qilu Hospital, Cheeloo College of MedicineShandong UniversityJinanChina
- Health Management Center (East Area)Qilu Hospital of Shandong UniversityJinanChina
| | - Yajuan Wang
- Department of Geriatric Medicine, Qilu Hospital, Cheeloo College of MedicineShandong UniversityJinanChina
- Key Laboratory of Cardiovascular Proteomics of Shandong Province, Qilu Hospital, Cheeloo College of MedicineShandong UniversityJinanChina
- Jinan Clinical Research Center for Geriatric Medicine (202132001)JinanChina
| | - Fei Yu
- Department of Geriatric Medicine, Qilu Hospital, Cheeloo College of MedicineShandong UniversityJinanChina
- Key Laboratory of Cardiovascular Proteomics of Shandong Province, Qilu Hospital, Cheeloo College of MedicineShandong UniversityJinanChina
- Jinan Clinical Research Center for Geriatric Medicine (202132001)JinanChina
| | - Chunli Fu
- Department of Geriatric Medicine, Qilu Hospital, Cheeloo College of MedicineShandong UniversityJinanChina
- Key Laboratory of Cardiovascular Proteomics of Shandong Province, Qilu Hospital, Cheeloo College of MedicineShandong UniversityJinanChina
- Jinan Clinical Research Center for Geriatric Medicine (202132001)JinanChina
| | - Xin Yu
- Department of Geriatric Medicine, Qilu Hospital, Cheeloo College of MedicineShandong UniversityJinanChina
- Key Laboratory of Cardiovascular Proteomics of Shandong Province, Qilu Hospital, Cheeloo College of MedicineShandong UniversityJinanChina
- Jinan Clinical Research Center for Geriatric Medicine (202132001)JinanChina
| | - Xiaoli Li
- Department of PharmacyQilu Hospital of Shandong UniversityJinanChina
| | - Chaochao Dai
- Key Laboratory of Cardiovascular Proteomics of Shandong Province, Qilu Hospital, Cheeloo College of MedicineShandong UniversityJinanChina
| | - Jie Wang
- Key Laboratory of Cardiovascular Proteomics of Shandong Province, Qilu Hospital, Cheeloo College of MedicineShandong UniversityJinanChina
| | - Haiqing Gao
- Department of Geriatric Medicine, Qilu Hospital, Cheeloo College of MedicineShandong UniversityJinanChina
- Key Laboratory of Cardiovascular Proteomics of Shandong Province, Qilu Hospital, Cheeloo College of MedicineShandong UniversityJinanChina
- Jinan Clinical Research Center for Geriatric Medicine (202132001)JinanChina
| | - Mei Cheng
- Department of Geriatric Medicine, Qilu Hospital, Cheeloo College of MedicineShandong UniversityJinanChina
- Key Laboratory of Cardiovascular Proteomics of Shandong Province, Qilu Hospital, Cheeloo College of MedicineShandong UniversityJinanChina
- Jinan Clinical Research Center for Geriatric Medicine (202132001)JinanChina
| |
Collapse
|
2
|
Agrawal S, Bisen AC, Biswas A, Sanap SN, Verma SK, Kumar M, Jaiswal S, Kumar A, Narender T, Bhatta RS. Simultaneous pharmacokinetic assessment of phytopharmaceuticals in fenugreek extract using LC-MS/MS in Sprague-Dawley rats. Biomed Chromatogr 2023; 37:e5600. [PMID: 36760100 DOI: 10.1002/bmc.5600] [Citation(s) in RCA: 8] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/07/2022] [Revised: 02/03/2023] [Accepted: 02/07/2023] [Indexed: 02/11/2023]
Abstract
Fenugreek seeds are used in numerous marketed herbal formulations with therapeutic benefits. Some of its bioactive components such as 4-hydroxyisoleucine, trigonelline, raffinose, and pinitol are reported to possess potential therapeutic activities, such as antibacterial, antidiabetic, stomach stimulant, and anti-invasive, against hyperandrogenism and other allied diseases, including polycystic ovary syndrome. A fully validated, selective, and sensitive bioanalytical method for the simultaneous rapid quantification of the aforementioned bioactive components has been developed using hyphenated liquid chromatography electrospray tandem mass spectrometry. The analytes were separated within 5 min using gradient elution in a C18 column at a flow rate of 0.5 ml/min. Plasma protein precipitation technique was employed to isolate the analytes from the samples. Oral pharmacokinetic profile of the four bioactive components in Sprague-Dawley rats was further evaluated using noncompartmental analysis using Phoenix WinNonlin software.
Collapse
Affiliation(s)
- Sristi Agrawal
- Pharmaceutics and Pharmacokinetics Division, CSIR-Central Drug Research Institute, Lucknow, India.,Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, India
| | - Amol Chhatrapati Bisen
- Pharmaceutics and Pharmacokinetics Division, CSIR-Central Drug Research Institute, Lucknow, India.,Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, India
| | - Arpon Biswas
- Pharmaceutics and Pharmacokinetics Division, CSIR-Central Drug Research Institute, Lucknow, India.,Jawaharlal Nehru University, New Delhi, India
| | - Sachin Nashik Sanap
- Pharmaceutics and Pharmacokinetics Division, CSIR-Central Drug Research Institute, Lucknow, India.,Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, India
| | - Sarvesh Kumar Verma
- Pharmaceutics and Pharmacokinetics Division, CSIR-Central Drug Research Institute, Lucknow, India.,Jawaharlal Nehru University, New Delhi, India
| | - Mukesh Kumar
- Pharmaceutics and Pharmacokinetics Division, CSIR-Central Drug Research Institute, Lucknow, India.,Jawaharlal Nehru University, New Delhi, India
| | - Shubham Jaiswal
- Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, India.,Division of Medicinal and Process Chemistry, CSIR-Central Drug Research Institute, Lucknow, India
| | - Ashok Kumar
- Division of Medicinal and Process Chemistry, CSIR-Central Drug Research Institute, Lucknow, India
| | - Tadigoppula Narender
- Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, India.,Division of Medicinal and Process Chemistry, CSIR-Central Drug Research Institute, Lucknow, India
| | - Rabi Sankar Bhatta
- Pharmaceutics and Pharmacokinetics Division, CSIR-Central Drug Research Institute, Lucknow, India.,Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, India
| |
Collapse
|
3
|
Xiang J, Wu M, Wang J, Lin M, Sun M, Li X, Xing R, Guo R, Gu J, Lyu T, Wang L, Shi X. Pharmacokinetics, bioavailability, and plasma protein binding study of glytrexate, a novel multitarget antifolate. Front Pharmacol 2022; 13:1001308. [PMID: 36267288 PMCID: PMC9577195 DOI: 10.3389/fphar.2022.1001308] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/23/2022] [Accepted: 09/15/2022] [Indexed: 11/13/2022] Open
Abstract
Glytrexate, developed by our team, as a novel multitarget folate antagonist, has inhibitory effects on a variety of cancer cell types, especially KB tumor cells (IC50 0.078 nM), and thus has antitumor drug development prospects. However, its pharmacokinetics and plasma protein binding properties remain unknown. In this study a selective and sensitive liquid chromatography-tandem mass spectrometry (LC‒MS/MS) method was developed and verified to facilitate biological analysis. The bioanalysis method was applied to evaluate the stability, plasma protein binding, and pharmacokinetics of glytrexate. Glytrexate is more stable in human plasma than in rat plasma and in human liver microsomes. The binding of glytrexate to human plasma proteins was higher than that to rat plasma proteins, both of which were less than 30%, suggesting that glytrexate may be at a higher concentration at the pharmacologic target receptor(s) in tissues. Pharmacokinetic characteristics were determined by noncompartmental analysis after administration of single oral (12.5, 25 and 50 mg/kg) and intravenous (2 mg/kg) doses in rats. According to the rat oral pharmacokinetic characteristics, glytrexate had linear dynamics in a dose range of 12.5–50 mg/kg and a poor oral bioavailability of 0.57–1.15%. The investigation revealed that the intravenous half-life, AUC, and Cmax of glytrexate were higher than those of pemetrexed. Pemetrexed is generally produced as an injection preparation. This provides ideas for the development of glytrexate formulations. Therefore, glytrexate injection has clinical application prospects compared to oral administration. This study provides a basis for further investigations into the pharmacological effects and clinical uses of glytrexate.
Collapse
Affiliation(s)
- Jiahong Xiang
- Key Laboratory of Innovative Drug Research and Evaluation in Hebei Province, School of Pharmaceutical Sciences, Hebei Medical University, Shijiazhuang, China
- Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Hebei Medical University, Shijiazhuang, China
| | - Mengqi Wu
- Key Laboratory of Innovative Drug Research and Evaluation in Hebei Province, School of Pharmaceutical Sciences, Hebei Medical University, Shijiazhuang, China
- Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Hebei Medical University, Shijiazhuang, China
| | - Jianchao Wang
- Key Laboratory of Innovative Drug Research and Evaluation in Hebei Province, School of Pharmaceutical Sciences, Hebei Medical University, Shijiazhuang, China
- Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Hebei Medical University, Shijiazhuang, China
| | - Mengmeng Lin
- Key Laboratory of Innovative Drug Research and Evaluation in Hebei Province, School of Pharmaceutical Sciences, Hebei Medical University, Shijiazhuang, China
- Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Hebei Medical University, Shijiazhuang, China
| | - Mengmeng Sun
- Department of General Practice, The Second Hospital, Hebei Medical University, Shijiazhuang, China
| | - Xin Li
- Key Laboratory of Innovative Drug Research and Evaluation in Hebei Province, School of Pharmaceutical Sciences, Hebei Medical University, Shijiazhuang, China
| | - Ruijuan Xing
- Key Laboratory of Innovative Drug Research and Evaluation in Hebei Province, School of Pharmaceutical Sciences, Hebei Medical University, Shijiazhuang, China
- Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Hebei Medical University, Shijiazhuang, China
| | - Ran Guo
- Key Laboratory of Innovative Drug Research and Evaluation in Hebei Province, School of Pharmaceutical Sciences, Hebei Medical University, Shijiazhuang, China
- Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Hebei Medical University, Shijiazhuang, China
| | - Jianmin Gu
- Key Laboratory of Innovative Drug Research and Evaluation in Hebei Province, School of Pharmaceutical Sciences, Hebei Medical University, Shijiazhuang, China
- Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Hebei Medical University, Shijiazhuang, China
| | - Tao Lyu
- Key Laboratory of Innovative Drug Research and Evaluation in Hebei Province, School of Pharmaceutical Sciences, Hebei Medical University, Shijiazhuang, China
| | - Lei Wang
- Key Laboratory of Innovative Drug Research and Evaluation in Hebei Province, School of Pharmaceutical Sciences, Hebei Medical University, Shijiazhuang, China
- Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Hebei Medical University, Shijiazhuang, China
- *Correspondence: Xiaowei Shi, ; Lei Wang,
| | - Xiaowei Shi
- Key Laboratory of Innovative Drug Research and Evaluation in Hebei Province, School of Pharmaceutical Sciences, Hebei Medical University, Shijiazhuang, China
- Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Hebei Medical University, Shijiazhuang, China
- *Correspondence: Xiaowei Shi, ; Lei Wang,
| |
Collapse
|
4
|
Pandi A, Sattu K, Kalappan VM, Lal V, Varikasuvu SR, Ganguly A, Prasad J. Pharmacological effects of D-Pinitol - A comprehensive review. J Food Biochem 2022; 46:e14282. [PMID: 35735162 DOI: 10.1111/jfbc.14282] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/16/2022] [Revised: 05/07/2022] [Accepted: 05/17/2022] [Indexed: 11/27/2022]
Abstract
In recent years, the application of phytochemicals to prevent or treat diseases has received greater attention. These phytochemicals have little or no toxicity against healthy tissues and are thus considered as ideal compounds. An impressive number of modern drugs are obtained from natural sources based on their traditional value. D-Pinitol is a natural compound that is derived from soy and soy products. It is a potentially active molecule that belongs to the class of inositols. D-pinitol has been pharmacologically evaluated for its potent antioxidant, anti-diabetic, anti-inflammatory, anti-cancer, hepatoprotective, cardioprotective, renoprotective, neuroprotective, immunosuppressive, and anti-osteoporotic efficacies. This review is an attempt to validate the plausible pharmacological effects of D-pinitol using various in vivo and in vitro studies. PRACTICAL IMPLICATIONS: The consumption of plant-based products has been significantly increased all over the world. The active phytochemicals that are found in plants are stated to have numerous health promoting functions for the treatment of diabetes, cancer, inflammation, cardiac diseases, liver dysfunction, and many other. D-Pinitol is abundantly present in soybeans that possess notable therapeutic activities. Understanding the effects of D-Pinitol would potentially help in applying this compound in clinical research for the treatment of different disorders.
Collapse
Affiliation(s)
- Anandakumar Pandi
- Department of Biochemistry, All India Institute of Medical Sciences (AIIMS)-Deoghar, Deoghar, Jharkhand, India
| | - Kamaraj Sattu
- Department of Biotechnology, Periyar University, PG Extension centre, Dharmapuri, Tamilnadu, India
| | - Vanitha M Kalappan
- Formerly, Department of Medical Biochemistry, University of Madras, Taramani campus, Chennai, Tamilnadu, India
| | - Vanita Lal
- Department of Biochemistry, All India Institute of Medical Sciences (AIIMS)-Deoghar, Deoghar, Jharkhand, India
| | - Seshadri R Varikasuvu
- Department of Biochemistry, All India Institute of Medical Sciences (AIIMS)-Deoghar, Deoghar, Jharkhand, India
| | - Anirban Ganguly
- Department of Biochemistry, All India Institute of Medical Sciences (AIIMS)-Deoghar, Deoghar, Jharkhand, India
| | - Jitender Prasad
- Department of Biochemistry, All India Institute of Medical Sciences (AIIMS)-Deoghar, Deoghar, Jharkhand, India
| |
Collapse
|
5
|
Azab A. D-Pinitol-Active Natural Product from Carob with Notable Insulin Regulation. Nutrients 2022; 14:nu14071453. [PMID: 35406064 PMCID: PMC9003036 DOI: 10.3390/nu14071453] [Citation(s) in RCA: 13] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/03/2022] [Revised: 03/28/2022] [Accepted: 03/29/2022] [Indexed: 02/06/2023] Open
Abstract
Carob is one of the major food trees for peoples of the Mediterranean basin, but it has also been traditionally used for medicinal purposes. Carob contains many nutrients and active natural products, and D-Pinitol is clearly one of the most important of these. D-Pinitol has been reported in dozens of scientific publications and its very diverse medicinal properties are still being studied. Presently, more than thirty medicinal activities of D-Pinitol have been reported. Among these, many publications have reported the strong activities of D-Pinitol as a natural antidiabetic and insulin regulator, but also as an active anti-Alzheimer, anticancer, antioxidant, and anti-inflammatory, and is also immune- and hepato-protective. In this review, we will present a brief introduction of the nutritional and medicinal importance of Carob, both traditionally and as found by modern research. In the introduction, we will present Carob’s major active natural products. The structures of inositols will be presented with a brief literature summary of their medicinal activities, with special attention to those inositols in Carob, as well as D-Pinitol’s chemical structure and its medicinal and other properties. D-Pinitol antidiabetic and insulin regulation activities will be extensively presented, including its proposed mechanism of action. Finally, a discussion followed by the conclusions and future vision will summarize this article.
Collapse
|